Post-transplant hyperlipidaemia.
The correction of post-transplant hyperlipidaemia warrants the judicious and timely use of pharmacological agents with dietary modification and exercise. Reduction in hyperlipidaemia may have some role in decreasing the incidence of chronic rejection of allografts. The awareness that the morbidity and mortality of atherosclerotic disease may be lowered by active intervention will result in a better quality of life for transplant recipients.
Jindal
R M
RM
Department of Surgery, Indiana University School of Medicine, Indianapolis 46202, USA.
D016572:Cyclosporine / Q000009:adverse effects; D048909:Diabetes Complications; D006084:Graft Rejection; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology* / Q000628:therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016377:Organ Transplantation; D016559:Tacrolimus / Q000009:adverse effects
D000960:Hypolipidemic Agents; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus